We evaluated effects of carbamazepine and its metabolite, carbamazepine 10,11-epoxide, on the measurement of tricyclic antidepressant (TCA) concentrations in serum using the fluorescence polarization immunoassay (FPIA). We determined apparent TCA concentrations in 30 patients who were receiving carbamazepine but no TCAs. Carbamazepine concentrations ranged from 1.4 to 20.9 µg/mL (5.9-88.4 µmol/L); the observed apparent TCA concentrations ranged from 31.8 to 130.1 ng/mL (113.4-463.9 Carbamazepine, an anticonvulsant, has structural similarity to tricyclic antidepressants (TCAs). Carbamazepine also frequently is added to existing TCA therapy. 1 Carbamazepine, like lithium, might help some people with episodic behavioral lack of control and aggression, even in the absence of epileptic, affective, or organic features. 2 Data from controlled studies suggest that carbamazepine is superior to placebo, equivalent to neuroleptics, and comparable to lithium for the treatment of mania. Carbamazepine also is effective as an antidepressant and for prophylaxis. 3 TCAs and anticonvulsants such as carbamazepine also are used in the treatment of pain in polyneuropathy. 4 TCAs have a narrow therapeutic window, eg, amitriptyline has a therapeutic range of 120 to 250 ng/mL (433-903 nmol/L), and the toxic range is more than 500 ng/mL (>1,805 nmol/L). Gold et al 5 proposed a narrower therapeutic range for nortriptyline (90-130 ng/mL [342-494 nmol/L]) to avoid toxic effects. The cardiac toxic effects of TCAs are well documented in the literature. 6,7 TCAs also can induce seizures, and the incidence of seizures can be reduced to 0.4% by therapeutic drug monitoring of TCA concentrations. 8 Preskorn et al 9 reported that a cost-benefit analysis supports the cost-effectiveness of therapeutic drug monitoring of TCA concentrations.
Carbamazepine, an anticonvulsant, has structural similarity to tricyclic antidepressants (TCAs). Carbamazepine also frequently is added to existing TCA therapy. 1 Carbamazepine, like lithium, might help some people with episodic behavioral lack of control and aggression, even in the absence of epileptic, affective, or organic features. 2 Data from controlled studies suggest that carbamazepine is superior to placebo, equivalent to neuroleptics, and comparable to lithium for the treatment of mania. Carbamazepine also is effective as an antidepressant and for prophylaxis. 3 TCAs and anticonvulsants such as carbamazepine also are used in the treatment of pain in polyneuropathy. 4 TCAs have a narrow therapeutic window, eg, amitriptyline has a therapeutic range of 120 to 250 ng/mL (433-903 nmol/L), and the toxic range is more than 500 ng/mL (>1,805 nmol/L). Gold et al 5 proposed a narrower therapeutic range for nortriptyline (90-130 ng/mL [342-494 nmol/L]) to avoid toxic effects. The cardiac toxic effects of TCAs are well documented in the literature. 6, 7 TCAs also can induce seizures, and the incidence of seizures can be reduced to 0.4% by therapeutic drug monitoring of TCA concentrations. 8 Preskorn et al 9 reported that a cost-benefit analysis supports the cost-effectiveness of therapeutic drug monitoring of TCA concentrations.
TCA concentrations in serum or plasma can be determined by using high-performance liquid chromatography (HPLC). De la Torre et al 10 reported a method using capillary gas chromatography and nitrogen-phosphorus detection for the determination of TCA concentrations in human plasma samples. Although the manufacturer of a polyclonal fluorescence polarization immunoassay (FPIA; Abbott Laboratories, Abbott Park, IL) for TCA only recommends its use in the diagnosis of overdose, the assay, nevertheless, is used in therapeutic drug monitoring. 11 Rao et al 12 used the FPIA for TCAs to demonstrate that low serum levels of TCAs in amitriptyline-and doxepin-treated patients with depressive syndromes were associated with lack of response. Radziwon-Zaleska et al 13 also used the FPIA for TCAs to evaluate the clinical usefulness of therapeutic drug monitoring in the management of depression.
The interference of carbamazepine with the tricyclic FPIA has been studied. Chattergoon et al 14 reported false-positive TCA levels of 80 ng/mL (285 nmol/L) and 130 ng/mL (464 nmol/L) using the FPIA in 2 patients who never received TCAs. Fleischman and Chiang 15 reported a case of carbamazepine overdose in which the positive TCA serum concentration and the knowledge of cross-reactivity between carbamazepine and the TCA assay was the key to the diagnosis of the cause of altered mental status. Matos et al 16 reported 3 cases in which false-positive TCA levels led to the diagnosis of carbamazepine intoxication. We studied in detail the effects of carbamazepine and its metabolite, carbamazepine 10,11-epoxide, on serum TCA determination using the FPIA, which is used widely in clinical laboratories. We also explored the possibility of estimating the true concentration of TCAs in the presence of carbamazepine by using a mathematical model.
Materials and Methods
Carbamazepine, carbamazepine 10,11-epoxide, and amitriptyline hydrochloride were purchased from Sigma Chemical, St Louis, MO. The FPIA kits for TCA and carbamazepine were purchased from Abbott Laboratories, and both assays were run using an AxSYM analyzer (Abbott Laboratories). Standard solutions of carbamazepine and carbamazepine 10,11-epoxide were prepared in absolute ethanol (1 mg/mL each). A standard solution of amitriptyline (1 mg/mL) was prepared in distilled water. Later, that standard solution was diluted further with distilled water to prepare a working solution. The concentration of amitriptyline in the working solution was 10 µg/mL.
We used serum specimens from 35 patients who were receiving carbamazepine but no TCAs. We also prepared 3 serum pools from patients taking TCAs but no carbamazepine. These specimens are submitted routinely to our toxicology laboratory for therapeutic drug monitoring. We used leftover specimens for this study after all tests ordered by clinicians were performed and all results reported. These specimens otherwise would be discarded. The patients were receiving a variety of TCAs, including amitriptyline, protriptyline, and imipramine. We also supplemented aliquots of drug-free serum pools with various amounts of drugs.
The FPIA for TCA uses a polyclonal antibody (rabbit) against TCA and has a sensitivity of 20 ng/mL (71.3 nmol/L). Therefore, any TCA concentration less than 20 ng/mL (71.3 nmol/L) was scored as "none detected." This assay is linear up to a serum TCA concentration of 1,000 ng/mL (3,566 nmol/L). The FPIA for carbamazepine uses a sheep polyclonal antibody against carbamazepine. The assay is linear up to a serum carbamazepine concentration of 20 µg/mL (84.6 µmol/L), and the sensitivity of this assay is 0.5 µg/mL (2.1 µmol/L).
We measured apparent TCA concentrations in samples from 30 patients receiving carbamazepine but no TCA using the FPIA. In the next experiment, we supplemented aliquots of drug-free serum with various concentrations of carbamazepine or carbamazepine 10,11-epoxide, and apparent TCA concentrations again were measured using the FPIA. Because the cross-reactivity of an agent should be tested in the presence of the primary analyte, 17 in another set of experiments, we supplemented 2 different serum pools prepared from patients receiving TCA with known concentrations of carbamazepine or carbamazepine 10,11-epoxide. To avoid a matrix problem, we added the required amount of standard solution of carbamazepine or carbamazepine 10,11-epoxide in a test tube, and ethyl alcohol was evaporated to dryness under nitrogen. Then the dry residue was reconstituted with the desired amount of the TCA serum pool. Each measurement of the TCA concentration was performed in triplicate, and the values were expressed as the mean and 1 SD.
In another experiment, we added known amounts of amitriptyline to 5 serum specimens containing known amounts of carbamazepine. These specimens were prepared from samples from patients receiving carbamazepine but no TCAs. We calculated true TCA concentrations from the observed TCA concentrations and the equation that we developed. The calculated TCA concentration was compared with the target TCA concentration (amount of amitriptyline added).
For the next set of experiments, we added 500-µL aliquots of the third TCA serum pool (prepared from patients receiving TCAs) to each 500-µL aliquot of 4 serum specimens containing carbamazepine but no TCAs. We also added 500 µL of drug-free serum to 500-µL aliquots of the third TCA pool to determine the target TCA concentration after dilution.
We added a high amount of amitriptyline in 2 aliquots of a drug-free serum pool to study the effect of high TCA concentrations on the FPIA for carbamazepine. High concentrations of imipramine also were added in 2 other aliquots of drug-free serum. We used a conversion factor of 3.566 for converting TCA concentrations expressed as nanograms per milliliter to nanomoles per liter as recommended in the package insert of the TCA assay (Abbott Laboratories).
To determine whether the cross-reactivity of carbamazepine and carbamazepine 10,11-epoxide with the TCA assay varies significantly between different lot numbers, we compared apparent TCA concentrations observed in the serum samples of 5 patients (cases 31-35) using an old lot (No. 9625Q100) and a new lot (No. 03734Q100). The new lot of reagent was purchased 3 months after the old lot was purchased. We also added carbamazepine or carbamazepine 10,11-epoxide to aliquots of drug-free serum and compared apparent TCA concentrations obtained by using the old lot and the new lot.
Statistical analysis was performed using the 2-tailed Student t test. We considered a difference statistically significant only at a 95% confidence level or higher (P < .05).
Results
We observed significant interference of carbamazepine with the FPIA for TCA. For example, a patient with a subtherapeutic concentration of carbamazepine of 6.5 µg/mL (27.5 µmol/L) showed an apparent TCA concentration of 50.7 ng/mL (180.8 nmol/L). Another specimen containing 17.5 µg/mL (74.0 µmol/L) of carbamazepine showed an apparent TCA concentration of 124.6 ng/mL (444.3 nmol/L) ❚Table 1❚. These values are clinically significant owing to the narrow therapeutic range of TCAs.
Carbamazepine showed significantly higher cross-reactivity with the TCA assay than its active metabolite, carbamazepine 10,11-epoxide. For example, when 40 µg/mL (169.2 µmol/L) of carbamazepine was added to an aliquot of drug-free serum, the observed apparent TCA concentration was 176.8 ng/mL (630.5 nmol/L). In contrast, in the presence of 40 µg/mL (158.4 µmol/L) of carbamazepine 10,11-epoxide, the observed apparent TCA concentration was only 43.3 ng/mL (154.4 nmol/L) ❚Table 2❚.
Rigorous characterization of interference in an immunoassay due to a cross-reactant should be performed in the presence of the primary analyte. 17 Therefore, we added these cross-reactants (carbamazepine or its metabolite) to TCA pools prepared from samples from patients receiving TCAs and then measured apparent TCA concentrations for comparison with the original TCA concentrations. We observed significant false elevation of apparent TCA concentrations even with a subtherapeutic concentration of carbamazepine. For example, the TCA concentration in TCA pool 1 was 125.6 ng/mL (447.9 nmol/L). In the presence of only 5.0 µg/mL (21.2 µmol/L) of carbamazepine, the apparent TCA level was increased falsely to 163.7 ng/mL (583.8 nmol/L), a difference that was statistically and clinically significant. In the presence of 20.0 µg/mL (84.6 µmol/L) of carbamazepine, the apparent TCA concentration was 241.9 ng/mL (862.6 nmol/L). As expected, the metabolite of carbamazepine, carbamazepine 10,11-epoxide, showed only a modest interference with the TCA measurement. In the presence of 20 µg/mL (79.2 µmol/L) of carbamazepine 10,11-epoxide, the observed TCA concentration was 135.2 ng/mL (482.1 nmol/L), which was only a 7.6% increase over the control value of 125.6 ng/mL (447.9 nmol/L) ❚Table 3❚.
By using the observed carbamazepine concentrations (µmol/L) as the x-axis and the observed TCA concentrations (nmol/L) as the y-axis, we observed the following regression equation ❚Figure 1❚: y + 4.12x + 100.8 (r = 0.94; r 2 = 0.88) By using the observed carbamazepine concentrations (µg/mL) as the x-axis and the observed TCA concentrations (ng/mL) as the y-axis, we observed a second regression equation in the presence of carbamazepine by measuring the apparent TCA concentration using the FPIA for TCA and also determining the carbamazepine concentration using the FPIA for carbamazepine. For example, in 1 specimen, the concentration of carbamazepine was 16.9 µg/mL (71.5 µmol/L). This specimen was prepared from a sample from a patient receiving carbamazepine but who had never been exposed to TCA. When we supplemented this specimen with amitriptyline to achieve a final concentration of 125.0 ng/mL (445.8 nmol/L), the observed TCA concentration was 227.5 ng/mL (811.3 nmol/L), a value 82.0% higher than the target concentration. The concentration of carbamazepine as measured by the FPIA assay was 71.5 µg/mL. Therefore, by using the first regression equation, the contribution of this carbamazepine level in the TCA measurement should be as follows: y (TCA, in nmol/L) = 4.12 × (carbamazepine, in µmol/L) + 100. 8 Therefore, y = 4.12 × 71.5 + 100.8 = 395.4 nmol/L (calculated TCA due to carbamazepine).
True TCA Concentration = Observed TCA -Calculated TCA Concentration Therefore, the true TCA = 811.3 -395.4 = 415.9 nmol/L (target TCA, 445.8 nmol/L).
The observed value was 6.7% lower than the value predicted by the equation. We also observed good correlation between the calculated TCA concentration and the targeted TCA concentration in 4 other specimens studied, with the differences between predicted values and observed values ranging from 5.4% higher than the target value to 9.8% lower than the target value ❚Figure 3❚.
If the concentrations are expressed in traditional units, the second equation is effective for determining expected TCA concentrations in the presence of carbamazepine.
y (TCA, in ng/mL) = 4.87 × (carbamazepine, in µg/mL) + 28.27
Therefore, y = 4.87 × 16.9 + 28.27 = 110.6 ng/mL (calculated TCA due to carbamazepine).
True TCA Concentration = Observed TCA -Calculated TCA Concentration Therefore, the true TCA = 227.5 -110.5 = 117.0 ng/mL (target TCA, 125.0 ng/mL).
To determine whether a high concentration of TCA interferes with the FPIA for carbamazepine, we supplemented 2 aliquots of drug-free serum with amitriptyline to achieve very high concentrations. In 1 specimen, the observed TCA concentration was 2,463 ng/mL (8,783 nmol/L; target concentration, 2,538 ng/mL [9,050 nmol/L]) as measured by the FPIA for TCA. When we measured the apparent carbamazepine concentration using the FPIA for carbamazepine, the observed value was below the sensitivity of the assay. Therefore, we considered this result as none detected. Similarly, another aliquot of drug-free serum also supplemented with imipramine (target concentration, 2,030 ng/mL [7, 239 nmol/L]; observed concentration, 2,074 ng/mL [7, 395 nmol/L]) showed an apparent carbamazepine concentration below the detection limit of the FPIA for carbamazepine. As expected, none of the 3 serum pools prepared from samples from patients receiving various TCAs but no carbamazepine showed apparent cross-reactivity with the carbamazepine immunoassay.
To further validate the equation, we added 500-µL aliquots of the third TCA serum pool to each 500-µL aliquot of 4 serum specimens prepared from patients receiving carbamazepine but no TCAs. Then we measured the carbamazepine and TCA concentrations. Because even a high concentration of TCA does not interfere with the carbamazepine immunoassay, the observed carbamazepine concentrations after dilution of these specimens with serum containing TCA were valid concentrations. However, observed TCA concentrations were elevated falsely owing to the presence of carbamazepine. To establish the target TCA concentration, we added 500 µL of drug-free serum to another 500-µL aliquot of the TCA serum pool. The observed TCA concentration was 86 ng/mL (307 nmol/L). The original concentration of TCA in the third serum pool was 176.9 ng/mL (630.8 nmol/L). Therefore, the expected concentration after dilution was 88.5 ng/mL (315.6 nmol/L), which was in good agreement with the observed concentration of 86.1 ng/mL (307.0 nmol/L). Again, by using the equation, we observed a good correlation between the expected TCA and the observed TCA concentrations. For example, in 1 specimen, the carbamazepine concentration was 4.4 µg/mL (18.6 µmol/L). The observed TCA concentration was 140.8 ng/mL (502.1 nmol/L); however, the calculated TCA concentration was 90.9 ng/mL (324.1 nmol/L), which is in a good agreement with the expected TCA concentration of 88.5 ng/mL (315.6 nmol/L) ❚Figure 4❚.
To establish that the cross-reactivity of carbamazepine and carbamazepine 10,11-epoxide does not change significantly between different lots of TCA reagents, we compared apparent TCA concentrations in 5 specimens containing carbamazepine but no TCA (cases 31-35) using the old lot and the new lot. We observed comparable apparent TCA concentrations using the old lot and the new lot of reagent. For further comparison, we supplemented aliquots of the drug-free serum pool with various amounts of carbamazepine or carbamazepine 10,11-epoxide. Again, we observed comparable TCA concentrations using the old lot and the new lot ❚Table 4❚.
Discussion
The package insert from the TCA assay states that carbamazepine at a concentration of 20,000 ng/mL and carbamazepine 10,11-epoxide at a concentration of 100,000 ng/mL showed an apparent TCA concentration above the sensitivity of the assay (20 ng/mL). The package insert does not provide any detail or significance of carbamazepine interference in the serum TCA determination using the FPIA. Chattergoon et al 14 clearly showed with 2 patients that carbamazepine could cause significant apparent TCA concentrations. Our study with samples from 35 patients clearly confirms their initial findings. Moreover, when we added known amounts of carbamazepine in serum pools prepared from samples from patients taking TCAs but no carbamazepine, we observed clinically significant increases in apparent TCA concentrations, indicating that if a patient is concurrently taking carbamazepine and TCA, the FPIA for TCAs cannot be used for routine therapeutic drug monitoring. Moreover, in such a patient, a suspected overdose of TCA cannot be confirmed by using the FPIA because carbamazepine will significantly increase the apparent TCA concentration, even if the concentration of carbamazepine is therapeutic. Another limitation of the FPIA for TCA is the lack of specificity of the polyclonal antibody toward different formulations of TCA class. It detects all 4 major TCAs such as amitriptyline, nortriptyline, imipramine, and desipramine. The serum or plasma results reflect the total amount of TCA (parent drug + demethylated metabolite). Nevertheless, the TCA FPIA is used widely for quick assessment of TCA levels in many clinical laboratories, including ours. Then results are verified further in appropriate cases by using HPLC.
Because carbamazepine can be determined by the same instrument (AxSYM or TDx, Abbott Laboratories) that is used for TCA determination, and most clinical laboratories also routinely determine the carbamazepine concentration as a part of the menu for therapeutic drug monitoring, a quick determination of the carbamazepine value in a specimen in which the TCA level is unexpectedly high might indicate the source of the interference. Fortunately, TCAs, even at very high concentrations, do not interfere with the FPIA for carbamazepine. Therefore, by knowing the concentration of carbamazepine in the specimen, the true TCA concentration can be predicted easily by using our equation. Both the carbamazepine and TCA assays can be performed in less than half an hour after receiving the specimen, and this approach is much faster than measuring the TCA concentration by using HPLC or gas chromatography-mass spectrometry. These techniques can be used later for further verification of the initial results obtained by using the immunoassays and the regression equation.
It also is possible that the entire TCA level in a patient is due to the presence of carbamazepine. In this case, by knowing the carbamazepine concentration, the expected TCA level can be calculated easily by using the regression equation. If the calculated TCA concentration agrees with the observed TCA concentration, then the presence of the TCA as the cause of a suspected overdose could be ruled out.
By using the regression equation, the true TCA concentration can be estimated in the presence of the interfering drug carbamazepine, using the FPIA for TCA. This may be helpful in a suspected drug overdose situation or in a patient who might not be taking medication as directed. However, this approach has certain limitations owing to the inherent limitations of the FPIA for TCA, as well as the limitation in measuring the carbamazepine concentration using the FPIA, which is affected by the metabolite carbamazepine 10,11-epoxide. This may be a problem in patients with renal failure in whom significant increases in the metabolite concentration compared with the parent drug can be observed. Also, our equation was based on samples from patients with a highest observed carbamazepine concentration of 20.9 µg/mL (88.4 µmol/L). Therefore, if the carbamazepine concentration is much higher than this value, the equation might not be valid. For example, when we supplemented TCA pool 1 with 40.0 µg/mL (169.2 µmol/L) of carbamazepine, the observed apparent TCA concentration was 
